Organon (OGN)
Market Price (1/21/2026): $9.47 | Market Cap: $2.5 BilSector: Health Care | Industry: Pharmaceuticals
Organon (OGN)
Market Price (1/21/2026): $9.47Market Cap: $2.5 BilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 27%, Dividend Yield is 6.4%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 23%, FCF Yield is 23% | Weak multi-year price returns2Y Excs Rtn is -80%, 3Y Excs Rtn is -136% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 332% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.7%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.1% | |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15% | Key risksOGN key risks include [1] a substantial debt burden threatening its financial stability, Show more. | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Oncology Treatments, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 27%, Dividend Yield is 6.4%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 23%, FCF Yield is 23% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Oncology Treatments, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -80%, 3Y Excs Rtn is -136% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 332% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.7%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.1% |
| Key risksOGN key risks include [1] a substantial debt burden threatening its financial stability, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Organon (OGN) stock has lost about 10% since 9/30/2025 because of the following key factors:
1. Organon reported stronger-than-expected financial results for the third quarter of 2025 on November 10, 2025, exceeding analyst estimates for both earnings per share (EPS) and revenue.
2. The U.S. FDA granted approval for POHERDY (pertuzumab-dpzb) on November 17, 2025, marking it as the first biosimilar to PERJETA (pertuzumab) in the United States, which strengthened Organon's biosimilars portfolio.
Show more
1. Organon reported stronger-than-expected financial results for the third quarter of 2025 on November 10, 2025, exceeding analyst estimates for both earnings per share (EPS) and revenue.
2. The U.S. FDA granted approval for POHERDY (pertuzumab-dpzb) on November 17, 2025, marking it as the first biosimilar to PERJETA (pertuzumab) in the United States, which strengthened Organon's biosimilars portfolio.
Show more
Stock Movement Drivers
Fundamental Drivers
The 40.5% change in OGN stock from 10/31/2025 to 1/20/2026 was primarily driven by a 96.4% change in the company's P/E Multiple.| 10312025 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 6.73 | 9.46 | 40.52% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 6281.00 | 6301.00 | 0.32% |
| Net Income Margin (%) | 11.14% | 7.95% | -28.66% |
| P/E Multiple | 2.50 | 4.91 | 96.37% |
| Shares Outstanding (Mil) | 259.94 | 259.98 | -0.01% |
| Cumulative Contribution | 40.52% |
Market Drivers
10/31/2025 to 1/20/2026| Return | Correlation | |
|---|---|---|
| OGN | 40.5% | |
| Market (SPY) | -0.7% | 17.6% |
| Sector (XLV) | 7.7% | 31.4% |
Fundamental Drivers
The -2.0% change in OGN stock from 7/31/2025 to 1/20/2026 was primarily driven by a -33.3% change in the company's Net Income Margin (%).| 7312025 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 9.65 | 9.46 | -2.00% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 6294.00 | 6301.00 | 0.11% |
| Net Income Margin (%) | 11.92% | 7.95% | -33.27% |
| P/E Multiple | 3.32 | 4.91 | 47.90% |
| Shares Outstanding (Mil) | 257.86 | 259.98 | -0.82% |
| Cumulative Contribution | -2.01% |
Market Drivers
7/31/2025 to 1/20/2026| Return | Correlation | |
|---|---|---|
| OGN | -2.0% | |
| Market (SPY) | 7.5% | 6.0% |
| Sector (XLV) | 19.7% | 27.1% |
Fundamental Drivers
The -37.6% change in OGN stock from 1/31/2025 to 1/20/2026 was primarily driven by a -60.8% change in the company's Net Income Margin (%).| 1312025 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 15.17 | 9.46 | -37.64% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 6409.00 | 6301.00 | -1.69% |
| Net Income Margin (%) | 20.30% | 7.95% | -60.83% |
| P/E Multiple | 3.00 | 4.91 | 63.49% |
| Shares Outstanding (Mil) | 257.50 | 259.98 | -0.96% |
| Cumulative Contribution | -37.65% |
Market Drivers
1/31/2025 to 1/20/2026| Return | Correlation | |
|---|---|---|
| OGN | -37.6% | |
| Market (SPY) | 13.6% | 28.3% |
| Sector (XLV) | 7.2% | 46.7% |
Fundamental Drivers
The -63.6% change in OGN stock from 1/31/2023 to 1/20/2026 was primarily driven by a -50.5% change in the company's Net Income Margin (%).| 1312023 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 26.01 | 9.46 | -63.64% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 6292.00 | 6301.00 | 0.14% |
| Net Income Margin (%) | 16.07% | 7.95% | -50.52% |
| P/E Multiple | 6.54 | 4.91 | -25.00% |
| Shares Outstanding (Mil) | 254.35 | 259.98 | -2.21% |
| Cumulative Contribution | -63.65% |
Market Drivers
1/31/2023 to 1/20/2026| Return | Correlation | |
|---|---|---|
| OGN | -63.6% | |
| Market (SPY) | 72.9% | 28.4% |
| Sector (XLV) | 22.0% | 43.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OGN Return | -7% | -4% | -45% | 10% | -51% | 22% | -67% |
| Peers Return | 28% | 11% | 7% | 13% | 22% | -0% | 108% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| OGN Win Rate | 50% | 50% | 50% | 50% | 42% | 100% | |
| Peers Win Rate | 53% | 57% | 47% | 52% | 53% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| OGN Max Drawdown | -14% | -22% | -58% | -4% | -57% | 0% | |
| Peers Max Drawdown | -12% | -16% | -23% | -5% | -16% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | 0% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VTRS, PFE, ABBV, AMGN, LLY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/20/2026 (YTD)
How Low Can It Go
| Event | OGN | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -72.2% | -25.4% |
| % Gain to Breakeven | 259.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to VTRS, PFE, ABBV, AMGN, LLY
In The Past
Organon's stock fell -72.2% during the 2022 Inflation Shock from a high on 3/2/2022. A -72.2% loss requires a 259.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
AI Analysis | Feedback
```html- Merck's version of AbbVie, specializing in women's health and established medicines.
- Like Viatris, but spun out from Merck with a strong emphasis on women's health and biosimilars.
AI Analysis | Feedback
- Nexplanon/Implanon NXT: A long-acting reversible contraceptive implant that prevents pregnancy for up to three years.
- NuvaRing: A combined hormonal contraceptive vaginal ring used to prevent pregnancy.
- Follistim AQ/Puregon: A fertility treatment used to stimulate egg production in women and sperm production in men.
- Renflexis: A biosimilar used to treat various autoimmune diseases, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
- Ontruzant: A biosimilar used to treat certain types of HER2-positive breast cancer and gastric cancer.
- Established Brands: A diverse portfolio of legacy pharmaceutical products addressing various therapeutic areas, including cardiovascular, respiratory, dermatology, and non-opioid pain management.
AI Analysis | Feedback
Organon (OGN) Major Customers
Organon (OGN), as a pharmaceutical company, primarily sells its products to a concentrated number of large drug wholesalers. These wholesalers then distribute the products to pharmacies, hospitals, governmental agencies, and physicians. Therefore, Organon's major direct customers are other companies.
According to Organon's financial filings, the following three major drug wholesalers account for a significant portion of its U.S. net sales:
- AmerisourceBergen Corporation (Symbol: ABC)
- Cardinal Health, Inc. (Symbol: CAH)
- McKesson Corporation (Symbol: MCK)
AI Analysis | Feedback
- Merck & Co., Inc. (MRK)
AI Analysis | Feedback
Joe Morrissey, Interim Chief Executive Officer
Joe Morrissey was appointed Interim Chief Executive Officer of Organon in October 2025. Prior to this role, he served as the company's Executive Vice President and Head of Manufacturing and Supply.
Matthew Walsh, Chief Financial Officer
Matthew Walsh is responsible for the development and execution of Organon's financial strategy, focusing on driving profitability, shareholder value, and financial integrity. Before joining Organon, he held executive leadership positions as Executive Vice President and CFO at Allergan plc and Catalent, Inc. During his tenure at Allergan, he served until the company's sale to Abbvie in 2020. At Catalent, where he worked from 2008 to 2018, he oversaw the company's successful completion of the largest healthcare IPO of 2014. Earlier in his career, Mr. Walsh was President, CFO, and Acting CEO at Escala Group, Inc., and held various finance and leadership roles, including CFO, at GenTek, Inc. He has served on the board of directors of Certara, Inc., a public company provider of software and consulting services to the life sciences industry, since 2020, and was previously a board member of Multicolor Corporation.
Juan Camilo Arjona Ferreira, M.D., Executive Vice President and Head of Research & Development and Chief Medical Officer
Dr. Juan Camilo Arjona Ferreira serves as Organon's Executive Vice President and Head of Research & Development and Chief Medical Officer.
Rachel Stahler, Chief Digital & Growth Officer
Rachel Stahler is Organon's Chief Digital & Growth Officer, where she leads Business Technology for the company.
Deborah Telman, General Counsel and Head of Corporate Governance
Deborah Telman holds the position of General Counsel and Head of Corporate Governance for Organon.
AI Analysis | Feedback
Organon & Co. (OGN) faces several significant risks to its business operations and financial stability:
- High Debt Burden: A critical financial risk for Organon is its substantial debt load, which is a legacy of its spin-off and subsequent acquisitions. As of September 30, 2025, the company's total debt stood at approximately $8.83 billion. This high leverage significantly constrains strategic flexibility and makes the company vulnerable to rising interest rates, as a considerable portion of profits must be allocated to interest payments. Some analysts rate Organon's financial strength as poor, with a low interest coverage ratio, and an Altman Z-Score indicating potential financial distress.
- Reliance on Established Brands and Generic Competition: Organon's core business relies heavily on its Established Brands portfolio, which is highly susceptible to generic competition and government pricing policies. This ongoing erosion of older products leads to persistent pricing pressure and declining margins, making it challenging to maintain top-line stability. For instance, the Women's Health franchise, a key focus area, experienced a revenue decline in Q3 2025, largely due to a significant decrease in U.S. sales of the contraceptive implant, Nexplanon.
- Legal and Regulatory Risks, including Wholesaler Sales Practices: Organon has recently faced scrutiny and legal challenges, notably an investigation into improper wholesale sales practices for its Nexplanon product. This investigation found that certain U.S. wholesalers were allegedly asked to purchase more Nexplanon than needed at various times to meet revenue expectations. These findings led to a significant drop in Organon's stock price and the resignation of its CEO, highlighting concerns about internal control over financial reporting and potential class-action lawsuits.
AI Analysis | Feedback
The escalating and intensifying competition within the biosimilar market, driven by a growing number of new entrants and increasing pricing pressure, poses a clear emerging threat. Organon's biosimilar portfolio, which includes products like Hadlima (adalimumab-bwwd), Renflexis (infliximab), Ontruzant (trastuzumab), and Brenzys (etanercept), faces continuous market share erosion and pricing pressure as more biosimilar competitors launch their versions of these blockbuster biologics. This trend is particularly evident with the numerous biosimilar launches for adalimumab in 2023, significantly increasing market fragmentation and pricing pressure for all participants, including Organon.
AI Analysis | Feedback
Organon (OGN) operates in three main product categories: Women's Health, Biosimilars, and Established Brands. The addressable market sizes for these categories are as follows:
-
Women's Health:
- Globally, the women's health market was estimated at USD 49.33 billion in 2024 and is projected to reach USD 68.53 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2030.
- In North America, the market size was USD 18.00 billion in 2019.
-
Biosimilars:
- The global biosimilars market size was USD 34.43 billion in 2024 and is predicted to increase to approximately USD 175.99 billion by 2034, expanding at a CAGR of 17.78% from 2025 to 2034.
- In North America, the biosimilars market size accounted for USD 7.51 billion in 2024 and is expected to reach around USD 37.64 billion by 2034.
- The European biosimilars market size was USD 13.16 billion in 2024 and is projected to be worth around USD 64.82 billion by 2034.
- Specifically for the Humira biosimilar market in the U.S., it is potentially worth USD 18 billion by 2025.
- Established Brands: null
AI Analysis | Feedback
Organon (OGN) is anticipated to drive future revenue growth over the next two to three years through several key strategies:
- Expansion and Performance of the Biosimilars Portfolio: Organon expects continued strong growth from its biosimilars, notably Hadlima, which demonstrated significant year-over-year growth in Q2 2025. The company also plans to launch a denosumab biosimilar in late 2025, pending FDA approval, and a biosimilar for Perjeta in the European Union and Latin America in 2026, followed by the U.S. market. These launches and the ongoing performance of existing biosimilars are projected to be significant revenue contributors.
- Growth in Key Women's Health Products and Strategic Investments: While the Women's Health segment saw a slight decline in Q3 2025, Organon's fertility business experienced 15% constant currency growth in Q2 2025, and Nexplanon is on track to achieve at least $1 billion in revenue in 2025. The company is actively pursuing future growth opportunities in women's health biopharma, supported by capital freed up from debt reduction and the recent divestment of its JADA System, which is expected to close in Q1 2026. This strategic focus aims to enhance and expand its portfolio within women's health.
- Increased Uptake and Market Penetration of VTAMA: VTAMA (tapinarof) cream, a recently launched product for atopic dermatitis, has shown strong sequential and year-over-year revenue growth. Organon is making new investments in direct-to-consumer marketing, telehealth, and its sales force to further drive its uptake and market penetration. VTAMA is considered an important product for offsetting the loss of exclusivity of other products, such as Atozet, and is expected to contribute significantly to revenue growth.
AI Analysis | Feedback
Share Repurchases
- Organon has not reported any significant share repurchases over the last 3-5 years.
- The 5-Year Share Buyback Ratio for Organon was -0.40% as of June 2025, indicating no share buybacks or potential share issuance.
Share Issuance
- Organon was spun off from Merck on June 2, 2021, with Merck shareholders receiving one-tenth of a share of Organon common stock for every Merck common share outstanding.
Outbound Investments
- Organon completed the acquisition of Dermavant Sciences in October 2024 for $1.2 billion, enhancing its dermatology portfolio with VTAMA (tapinarof) cream.
- In March 2021, Organon acquired Alydia Health for $215 million, which developed a medical device for postpartum hemorrhage.
- Organon acquired Forendo Pharma for $75 million in November 2021, adding a clinical-stage compound for endometriosis.
- In November 2025, Organon announced an agreement to divest its JADA System for up to $465 million to Laborie.
Capital Expenditures
- Organon's capital expenditure for the trailing twelve months ended June 2025 was €-318.07 million (approximately $340 million).
- Capital expenditures in 2021 and 2022 primarily reflected investments in new capital projects aimed at establishing Organon as an independent company.
- The company estimated continued investment in new capital projects in 2023, particularly related to information technology, for ongoing projects to stand up Organon.
Latest Trefis Analyses
| Title | Topic | Date | |
|---|---|---|---|
| DASHBOARDS | |||
| Organon Stock (+8%): Sun Pharma Bid Rumors Spark an M&A Chase | Notification | ||
| Organon Earnings Notes | |||
| Organon Earnings Notes | |||
| Organon Earnings Notes | |||
| Organon Earnings Notes | |||
| null | |||
| null | |||
| Organon (OGN) Operating Cash Flow Comparison | Financials | ||
| Organon (OGN) Revenue Comparison | Financials | ||
| Organon (OGN) EBITDA Comparison | Financials | ||
| ARTICLES | |||
| Organon Stock To $7? | October 28th, 2025 | ||
| Organon Stock Fell 23% in a Day, What Now? | October 28th, 2025 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Organon
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 119.78 |
| Mkt Cap | 161.6 |
| Rev LTM | 44,615 |
| Op Inc LTM | 11,518 |
| FCF LTM | 5,988 |
| FCF 3Y Avg | 5,383 |
| CFO LTM | 12,008 |
| CFO 3Y Avg | 8,776 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.6% |
| Rev Chg 3Y Avg | 0.6% |
| Rev Chg Q | 5.2% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Mgn LTM | 24.1% |
| Op Mgn 3Y Avg | 23.6% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 20.7% |
| CFO/Rev 3Y Avg | 18.3% |
| FCF/Rev LTM | 13.9% |
| FCF/Rev 3Y Avg | 13.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 161.6 |
| P/S | 3.6 |
| P/EBIT | 14.1 |
| P/E | 20.1 |
| P/CFO | 12.3 |
| Total Yield | 5.2% |
| Dividend Yield | 3.4% |
| FCF Yield 3Y Avg | 6.1% |
| D/E | 0.4 |
| Net D/E | 0.3 |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA215272 | VTAMA | tapinarof | cream | 5232022 | -18.4% | -32.0% | -41.9% | -33.9% | -69.9% |
| NDA215650 | XACIATO | clindamycin phosphate | gel | 12072021 | 26.0% | 31.1% | -6.6% | -56.9% | -60.8% |
| NDA205641 | ASMANEX HFA | mometasone furoate | aerosol, metered | 4252014 | |||||
| NDA200153 | LIPTRUZET | atorvastatin calcium | tablet | 5032013 | |||||
| NDA022518 | DULERA | formoterol fumarate | aerosol, metered | 6222010 | |||||
| NDA021529 | IMPLANON | etonogestrel | implant | 7172006 | |||||
| NDA021313 | CLARINEX-D 12 HOUR | desloratadine | tablet, extended release | 2012006 | |||||
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Nexplanon/Implanon NXT | 830 | |||
| Atozet | 519 | |||
| Other | 440 | 146 | ||
| Singulair | 404 | |||
| Zetia | 322 | |||
| Cozaar/Hyzaar | 281 | |||
| Renflexis | 278 | |||
| Other Non-Opioid Pain, Bone and Dermatology | 275 | |||
| Nasonex | 266 | |||
| Follistim AQ | 262 | |||
| Arcoxia | 257 | |||
| Dulera | 194 | |||
| NuvaRing | 176 | |||
| Fosamax | 159 | |||
| Ontruzant | 155 | |||
| Other Women's Health | 147 | |||
| Other Cardiovascular | 139 | |||
| Clarinex | 136 | |||
| Marvelon/Mercilon | 134 | |||
| Vytorin | 129 | |||
| Propecia | 125 | |||
| Ganirelix Acetate Injection | 110 | |||
| Proscar | 97 | |||
| Diprospan | 91 | |||
| Brenzys | 73 | |||
| Rosuzet | 70 | |||
| Other Respiratory | 64 | |||
| Hadlima | 44 | |||
| Aybintio | 43 | |||
| Jada | 43 | |||
| Emgality/Rayvow | 0 | |||
| Vtama | 0 | |||
| Biosimilars | 481 | 424 | 330 | |
| Established Brands | 3,874 | 4,268 | 4,647 | |
| Women’s Health | 1,673 | 1,612 | 1,555 | |
| Total | 6,263 | 6,174 | 6,304 | 6,532 |
Price Behavior
Price Behavior
| Market Price | $9.46 | |
| Market Cap ($ Bil) | 2.5 | |
| First Trading Date | 05/14/2021 | |
| Distance from 52W High | -40.9% | |
| 50 Days | 200 Days | |
| DMA Price | $7.50 | $9.18 |
| DMA Trend | down | down |
| Distance from DMA | 26.2% | 3.0% |
| 3M | 1YR | |
| Volatility | 70.7% | 62.3% |
| Downside Capture | -45.12 | 126.86 |
| Upside Capture | -14.06 | 60.52 |
| Correlation (SPY) | 4.7% | 29.7% |
OGN Betas & Captures as of 12/31/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.85 | 1.49 | 0.36 | 0.68 | 0.93 | 0.92 |
| Up Beta | 2.46 | 4.66 | 0.93 | 0.47 | 0.88 | 0.81 |
| Down Beta | -0.07 | 0.14 | 0.24 | 0.37 | 0.94 | 0.81 |
| Up Capture | 20% | 141% | -79% | 18% | 36% | 35% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 9 | 18 | 24 | 56 | 117 | 354 |
| Down Capture | 171% | 85% | 112% | 140% | 120% | 108% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 11 | 21 | 37 | 67 | 129 | 391 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
nullBased On 5-Year Data
nullBased On 10-Year Data
nullEarnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/10/2025 | 13.7% | 11.4% | 6.2% |
| 8/5/2025 | -13.1% | -6.8% | 1.9% |
| 5/1/2025 | -26.9% | -32.3% | -28.5% |
| 2/13/2025 | 11.0% | 6.7% | 6.1% |
| 10/31/2024 | 4.7% | -11.9% | -9.9% |
| 8/6/2024 | -7.6% | -3.6% | 11.6% |
| 5/2/2024 | 3.6% | 8.2% | 14.8% |
| 2/15/2024 | 13.8% | 13.4% | 13.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 7 | 9 |
| # Negative | 9 | 11 | 9 |
| Median Positive | 9.0% | 8.2% | 11.6% |
| Median Negative | -9.2% | -8.9% | -16.1% |
| Max Positive | 13.8% | 13.4% | 14.8% |
| Max Negative | -26.9% | -32.3% | -28.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/10/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/06/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/02/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 02/28/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/01/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 08/07/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 05/03/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 02/26/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 11/03/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/09/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/05/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 02/27/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/04/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 08/05/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 05/06/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 03/21/2022 | 10-K (12/31/2021) |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cox, Carrie Smith | Executive Chair | IRA | Buy | 11132025 | 7.67 | 65,400 | 501,755 | 597,419 | Form |
| 2 | Cox, Carrie Smith | Direct | Buy | 5152025 | 8.07 | 12,469 | 100,591 | 100,591 | Form | |
| 3 | Falcione, Aaron | Chief Human Resources Officer | Direct | Buy | 5072025 | 8.77 | 5,500 | 48,235 | 552,279 | Form |
| 4 | Weaver, Kirke | Gen. Counsel & Corp. Secy. | Direct | Buy | 5072025 | 9.21 | 8,045 | 74,054 | 483,161 | Form |
| 5 | Karp, Daniel | Executive VP, Corp. Dev. | Direct | Buy | 5072025 | 8.24 | 3,500 | 28,828 | 384,398 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.